ArticleGut pathogens2020
Carvacrol ameliorates acute campylobacteriosis in a clinical murine infection model.
Article in Gut pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 38 citations in OpenAlex.
- Antibacterial properties ofFrontiers in pharmacology · 2026Review
- Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025Review
- Therapeutic effects of oral benzoic acid application during acute murine campylobacteriosis.European journal of microbiology & immunology · 2024Article
- Carvacrol prophylaxis improves clinical outcome and dampens apoptotic and pro-inflammatory immune responses upon Campylobacter jejuni infection of human microbiota-associated IL-10-/- mice.European journal of microbiology & immunology · 2024Article
- Oral curcumin ameliorates acute murine campylobacteriosis.Frontiers in immunology · 2024Article
- Oral treatment of human gut microbiota associated IL-10Frontiers in microbiology · 2024Article
- Oral application of carvacrol, butyrate, ellagic acid, and 2'-fucosyl-lactose to mice suffering from acute campylobacteriosis - Results from a preclinical placebo-controlled intervention study.European journal of microbiology & immunology · 2023Article
- Carvacrol protects mice against LPS-induced sepsis and attenuates inflammatory response in macrophages by modulating the ERK1/2 pathway.Scientific reports · 2023Article
- Molecular Targets inBiomolecules · 2023Review
- The Impact of Za'atar Antioxidant Compounds on the Gut Microbiota and Gastrointestinal Disorders: Insights for Future Clinical Applications.Antioxidants (Basel, Switzerland) · 2023Review
- Therapeutic Oral Application of Carvacrol Alleviates Acute Campylobacteriosis in Mice Harboring a Human Gut Microbiota.Biomolecules · 2023Article
- Combination of organic acids benzoate, butyrate, caprylate, and sorbate provides a novel antibiotics-independent treatment option in the combat of acute campylobacteriosis.Frontiers in microbiology · 2023Article
- Iron Deprivation by Oral Deferoxamine Application Alleviates Acute Campylobacteriosis in a Clinical MurineBiomolecules · 2022Article
- Antimicrobial effect of a drinking water additive comprising four organic acids on Campylobacter load in broilers and monitoring of bacterial susceptibility.Poultry science · 2022Article
- Therapeutic application of carvacrol: A comprehensive review.Food science & nutrition · 2022Review
- Less Pronounced Immunopathological Responses Following Oral Butyrate Treatment ofMicroorganisms · 2022Article
- Recent advances on the regulation of bacterial biofilm formation by herbal medicines.Frontiers in microbiology · 2022Review
- Review
- Disease-Alleviating Effects of Peroral Activated Charcoal Treatment in Acute Murine Campylobacteriosis.Microorganisms · 2021Article
- Immune-Modulatory Effects upon Oral Application of Cumin-Essential-Oil to Mice Suffering from Acute Campylobacteriosis.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of human infections with the zoonotic pathogen
resultsTo address this in a clinical murine infection model of acute campylobacteriosis, secondary abiotic IL-10
conclusionThe lowered
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.